Ep 36 - Adam May: The Bear Case on HIMS, GLP-1s, Legal Risk, and the Collapse of the Novo Deal
Hims House
00:00
Navigating Legal Complexities in HIMS Operations
This chapter explores the intricate legal issues surrounding HIMS, focusing on FDA compliance for compounded drugs and intellectual property challenges. The discussion highlights the tension between legal adherence and ethical considerations, along with the implications for personalized dosing practices. Additionally, the speakers consider the impact of recent disputes involving major pharmaceutical players and the broader industry landscape.
Transcript
Play full episode
